U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H9N4O4.Na
Molecular Weight 260.1819
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACEFYLLINE SODIUM

SMILES

[Na+].CN1C2=C(N(CC([O-])=O)C=N2)C(=O)N(C)C1=O

InChI

InChIKey=MSFVZSOKOXZSME-UHFFFAOYSA-M
InChI=1S/C9H10N4O4.Na/c1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15;/h4H,3H2,1-2H3,(H,14,15);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C9H9N4O4
Molecular Weight 237.1922
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Acefylline is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. Acephylline piperazine is a theophylline derivative with a direct bronchodilator action. It has the advantages over theophylline in being far less toxic and producing minimal gastric irritation. It is indicated for the treatment of asthma, emphysema, acute and chronic bronchitis associated with bronchospasm.Acefylline relaxes smooth muscles, relieves bronchospasm & has a stimulant effect on respiration. It stimulates the myocardium & central nervous system, decreases peripheral resistance & venous pressure & causes diuresis. The mechanism of action is still not clear, inhibition of phosphodiesterase with a resulting increase in intracellular cyclic AMP does occur, but not apparently at concentrations normally used for clinical effect. Other proposed mechanisms of action include adenosine receptor antagonism, prostaglandin antagonism & effects on intracellular calcium. Sodium phenobarbital is a non-selective central nervous system depressant that is primarily used as sedative-hypnotic.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
27.6 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Etaphylline
Primary
Etaphylline
Primary
Etaphylline
Primary
Etaphylline
PubMed

PubMed

TitleDatePubMed
Esterification of 7-theophyllineacetic acid with diethylene glycol monomethyl ether.
2006 Jun
Development and validation of chemometrics-assisted spectrophotometric and liquid chromatographic methods for the simultaneous determination of two multicomponent mixtures containing bronchodilator drugs.
2007 Feb 19
Acebrophylline: an airway mucoregulator and anti-inflammatory agent.
2007 Jun
Solid-state chemistry of ambroxol theophylline-7-acetate.
2007 May
Molecularly imprinted polymers for ochratoxin a extraction and analysis.
2010 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Dosage & route of administration & duration: The optimum therapeutic serum concentration is considered to range from 10 to 20 mcg/ml To avoid adverse effects the rate of infusion administration should not exceed 20 mg / min For I.M & slow I.V injection of 200 mg over at least 15 min. For IV infusion a loading dose of 4 mg/kg may be given over 20 to 30 min followed by a suggested maintenance dose of 0.5 mg /kg / hour reduced after 12 hours to 0.4 mg/kg/hour. Suggested Doses for children: 4mg/Kg by slow IV injection over at least 15 min or by infusion with a loading dose of 4 mg/kg followed by maintenance doses of: Children from 6 months to 6 years...................0.8 to 1 mg/kg/hour, reduced after the first 12 hours to 0.6 mg/kg/hour. Children over 6 years.....................................0.75 mg/kg/hour, reduced after the first 12 hours to 0.5 mg/kg/hour.
Route of Administration: Parenteral
In Vitro Use Guide
After topical application of a gel formulation containing 3% acefylline at the surface of reconstructed human epidermis, immunoblotting analysis showed an increase in the total amount of deiminated proteins, and confocal microscopy showed an enhanced deimination in the stratum corneum. This demonstrated the activation of PADs in living cells.
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:00:10 UTC 2019
Edited
by admin
on Tue Oct 22 00:00:10 UTC 2019
Record UNII
WA8729994I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACEFYLLINE SODIUM
WHO-DD  
Common Name English
ACEFYLLINE SODIUM SALT
MI  
Common Name English
7H-PURINE-7-ACETIC ACID, 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-, SODIUM SALT (1:1)
Common Name English
ACEFYLLINE SODIUM [WHO-DD]
Common Name English
ACEFYLLINE SODIUM SALT [MI]
Common Name English
STENOFILLINA
Common Name English
SODIUM THEOPHYLLINE-7-ACETATE
Systematic Name English
AMINODAL
Common Name English
Code System Code Type Description
CAS
837-27-4
Created by admin on Tue Oct 22 00:00:10 UTC 2019 , Edited by admin on Tue Oct 22 00:00:10 UTC 2019
PRIMARY
MERCK INDEX
M1295
Created by admin on Tue Oct 22 00:00:10 UTC 2019 , Edited by admin on Tue Oct 22 00:00:10 UTC 2019
PRIMARY Merck Index
PUBCHEM
23677981
Created by admin on Tue Oct 22 00:00:10 UTC 2019 , Edited by admin on Tue Oct 22 00:00:10 UTC 2019
PRIMARY
ECHA (EC/EINECS)
212-652-5
Created by admin on Tue Oct 22 00:00:10 UTC 2019 , Edited by admin on Tue Oct 22 00:00:10 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY